Analysts Set Liquidia Corporation (NASDAQ:LQDA) Target Price at $98.08

Liquidia Corporation (NASDAQ:LQDA) has been assigned a consensus recommendation of “Hold” from the eleven ratings firms that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, three have given a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $98.0833.

LQDA has been the topic of several recent analyst reports. Jefferies Financial Group reissued a “buy” rating and issued a $60.00 target price on shares of Liquidia in a research note on Monday, May 11th. Bank of America upped their price target on Liquidia from $79.00 to $92.00 and gave the company a “neutral” rating in a research report on Thursday, August 13th. Wells Fargo & Company lifted their price objective on Liquidia from $62.00 to $108.00 and gave the stock an “overweight” rating in a research report on Thursday, August 13th. Raymond James Financial reissued a “strong-buy” rating and set a $106.00 target price on shares of Liquidia in a research note on Thursday, August 13th. Finally, Zacks Research cut Liquidia from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 13th.

Liquidia Stock Up 0.0%

Shares of NASDAQ LQDA opened at $68.66 on Thursday. The firm’s fifty day moving average is $78.51 and its 200 day moving average is $58.11. Liquidia has a 52 week low of $21.15 and a 52 week high of $93.61. The company has a quick ratio of 2.12, a current ratio of 2.31 and a debt-to-equity ratio of 0.63. The company has a market cap of $6.15 billion, a price-to-earnings ratio of 50.12 and a beta of 0.53.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.02). The firm had revenue of $171.68 million for the quarter, compared to analysts’ expectations of $168.48 million. Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The company’s quarterly revenue was up 1842.1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.49) EPS. On average, equities research analysts expect that Liquidia will post 2.57 earnings per share for the current year.

Insiders Place Their Bets

In other Liquidia news, insider Rajeev Saggar sold 50,000 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $74.06, for a total transaction of $3,703,000.00. Following the transaction, the insider directly owned 142,265 shares of the company’s stock, valued at approximately $10,536,145.90. The trade was a 26.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jason Adair sold 73,631 shares of the business’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $69.09, for a total transaction of $5,087,165.79. Following the transaction, the insider directly owned 174,606 shares in the company, valued at approximately $12,063,528.54. The trade was a 29.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,539,210 shares of company stock valued at $111,412,994 over the last quarter. 25.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Liquidia

Institutional investors have recently bought and sold shares of the stock. California State Teachers Retirement System boosted its position in Liquidia by 8,055.4% during the 2nd quarter. California State Teachers Retirement System now owns 5,907,594 shares of the company’s stock valued at $471,012,000 after acquiring an additional 5,835,156 shares in the last quarter. TCG Crossover Management LLC bought a new position in shares of Liquidia in the 3rd quarter worth approximately $38,887,000. MPM Bioimpact LLC lifted its stake in shares of Liquidia by 600.4% in the 4th quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock valued at $48,316,000 after purchasing an additional 1,200,869 shares during the period. Voloridge Investment Management LLC purchased a new position in shares of Liquidia in the 3rd quarter valued at approximately $12,571,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Liquidia during the second quarter valued at approximately $29,694,000. 64.54% of the stock is owned by institutional investors.

Trending Headlines about Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: The FDA granted Fast Track designation to YUTREPIA (treprostinil inhalation powder) for systemic sclerosis-associated Raynaud’s phenomenon (SSc-RP). The designation provides more frequent FDA interactions and potentially enables rolling review, Priority Review or Accelerated Approval if applicable. FDA Grants Fast Track Designation to YUTREPIA
• Positive Sentiment: Liquidia plans to begin the approximately 75-patient RE-WARM Phase 2a dose-finding study in October 2026, targeting primary completion in February 2027. SSc-RP affects a substantial population, has no FDA-approved U.S. therapy and represents a potential expansion opportunity for YUTREPIA. Liquidia Gains FDA Fast Track for YUTREPIA
• Positive Sentiment: Coverage highlighted that the YUTREPIA launch is continuing to outperform expectations, supporting the investment case for Liquidia’s commercial execution and revenue growth. YUTREPIA Launch Continues to Outpace Expectations
• Neutral Sentiment: Analysts collectively maintain an average “Hold” rating, indicating that the positive regulatory and commercial developments are balanced by valuation, execution and clinical-development uncertainty. Liquidia Receives Average Hold Rating
• Negative Sentiment: Fast Track is not approval: YUTREPIA’s safety and efficacy for SSc-RP have not been established, and the company must still produce favorable Phase 2a and later-stage data. The indication therefore carries meaningful clinical and regulatory risk. Liquidia Receives FDA Fast Track Designation

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).